Targeting MET, vascular endothelial growth factor receptor (VEGFR) and AXL using cabozantinib resulted in decreased migration, invasion, and proliferation causing apoptotic cell death in naïve and therapy resistant head and neck cancer cells [46]. This evidence concerns the gene KDR and head and neck cancer.